Urokinase: Basic and Clinical Aspects

Proceedings of the Serono Symposia, Volume 48

Edited by

P.M. Mannucci and A.D'Angelo

Urokinase: Basic and Clinical Aspects

Proceedings of the Serono Symposia, Volume 48

Edited by

P.M. Mannucci and A.D'Angelo

Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Milan, Italy

1982



ACADEMIC PRESS

A Subsidiary of Harcourt Brace Jovanovich, Publishers

London New York Paris San Diego San Francisco São Paulo Sydney Tokyo Toronto

ACADEMIC PRESS INC. (LONDON) LTD. 24-28 OVAL ROAD LONDON NWI

U.S. Edition published by ACADEMIC PRESS INC. 111 FIFTH AVENUE NEW YORK, NEW YORK 10003

Copyright @ 1982 by Academic Press Inc. (London) Ltd.


All rights reserved

NO PART OF THIS BOOK MAY BE REPRODUCTED IN ANY FORM BY PHOTOSTAT, MICROFILM, OR BY ANY OTHER MEANS, WITHOUT WRITTEN PERMISSION FROM THE PUBLISHERS

British Library Cataloguing in Publication Data

Urokinase: basic and clinical aspects.—(Serono symposia; no. 48)
1. Urokinase—Congresses
I. Mannucci, P. M. II. D'Angelo, A. III. Series
612'.0151 RM666.P78

ISBN 0-12-469280-X LCCCN 81-68958





Urokinase: Basic and Clinical Aspects

发现在104次	
Standiers and Thrombosis Mills and Paren 1977	
Ausonay: Human Growth in Health and Obserder, Gerlott and Serial 1978	
Rocent Progress in Audiology, Equipment Statements 1979	. Fig
Flamin de se and Plangbook, Ver Sener and Brettlee 1979. Pumorassentete Antigent and their Specific Immend Response, Spreyflee and Front	
1879 Obesky et (Inidbood, Caronel, Laroh and Raul 1978	
The Endocane Function of the Human Adversal Cottex, James, Serio, Chasti and	
Name and a control of the logical and thintest Aspaces, Policy and March 2011 1212	
Perception and Remoduction, Carenza and Zichardta 1979	
Transfer and Representation Careata and Authority 200	
Research on Statemas Vol. VIII. Klodner, Lorder, and des Molen used Science 1992.	
1978. Sandramodias and Growth, Gloridno, Pan Welt and Mismin 1979.	
Sensioned the Action of Constanting of Paters, Canadiem and Billery 1980.	
Carly Charles Willer and Amora (846)	25
The state of the control of the state of the	36
The formume System Paraciness and Phiesipp of Bysispections, (Jorna and Estical,	
observe to the constitute of the contract of the Constitution of the contract	
THE PROPERTY OF THE PROPERTY O	
Capters Areas on Hypoglyceans and Captagen, Andread, Logebra and Marks 1980	
Find outwar and to stimum, This are and Lorent 1981	
Problems to Podentin Endocumology, La Cytest and Root 1980. Autgustinase Aspects of Endocrine Disorders, Fractical, Bootsteen Fents and Raschoes.	
그리고 있었다. 그리고 있는 그리고 있는 그리고 있는 그리고 있는 것이 없는 것이 없다. 그리고 있다면 없는 것	
Medical and Surgical Problems of Fortal Presentences, Ottob. State and Zipare 1980.	
Tak Hanna Passeria, Proteins and Homones, Mapper, Genezioni and Ocupalan	
Patrophy votor: Repudled of Repudled to Careffeed Athers of Assects, 'State of the Assects,' State of the Assects,' State of the Assects,' State of the Assects, 'State of the Assects,' State of the Assects,	
Thypian I by no. The Mercrosuse: as and Circa and Circa in, Gardeno: Man Well happens. Fiorethy January Mets and A Serossi a A Serossion. Constantiality.	
Harring Mais and A berosel & A beroscherons, Constantialers	
The Low I, System Bart in market and Chercher 1979	
Carrent View a optimizations of pirations of O. att., Marchit. Langua, Gliens and The Gon alottop System Position Proprieties and Ultraction	
。一个是是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一	
18.0 1 (19.0 pt) 19.0 pt	
The state of the s	



Recent Titles

10. Platelets and Thrombosis, Mills and Pareti 1977

11. Prolactin and Human Reproduction, Crosignani and Robyn 1977

- Recent Progress in Pediatric Endocrinology, Chiumello and Laron 1977
 Auxology: Human Growth in Health and Disorder, Gedda and Parisi 1978
- 14. Recent Progress in Andrology, Fabbrini and Steinberger 1979

15. Haemostasis and Thrombosis, Neri Serneri and Prentice 1979

16. Tumor-associated Antigens and their Specific Immune Response Spreafico and Arnon 1979

17. Obesity in Childhood, Cacciari, Laron and Raiti 1978

- The Endocrine Function of the Human Adrenal Cortex, James, Serio, Giusti and Martini 1978
- 19. Neuroendocrinology: Biological and Clinical Aspects, Polleri and MacLeod 1979

20A. Emotion and Reproduction, Carenza and Zichella 1979

20B. Emotion and Reproduction, Carenza and Zichella 1979

 Research on Steroids Vol. VIII. Klopper, Lerner, van der Molen and Sciarra 1979
 Clinical Psychoneuroendocrinology in Reproduction, Carenza, Pancheri and Zichella 1978

23. Somatomedins and Growth, Giordano, Van Wyk and Minuto 1979

24. Immunity and Atherosclerosis, Constantinides, Pratesi, Cavallero † and Di Perri 1980

25. Cryptorchidism, Bierich and Giarola 1979

26. Medical Complications of Obesity, Mancini, Lewis and Contaldo 1979

27. The Immune System: Functions and Therapy of Dysfunctions, Doria and Eshkol 1980

28. Obesity: Pathogenesis and Treatment, Enzi, Crepaldi, Pozza and Renold 1981

29. Pituitary Microadenomas, Faglia, Giovanelli and MacLeod 1980

30. Current Views on Hypoglycemia and Glucagon, Andreani, Lefebvre and Marks 1980

31. Fibrinolysis and Urokinase, Tilsner and Lenau 1981

32. Problems in Pediatric Endocrinology, La Cauza and Root 1980

 Autoimmune Aspects of Endocrine Disorders, Pinchera, Doniach, Fenzi and Baschieri 1981

34. Medical and Surgical Problems of Portal Hypertension, Orloff, Stipa and Ziparo 1980

 The Human Placenta: Proteins and Hormones, Klopper, Genazzani and Crosignani 1980

36. Pathophysiology of Puberty, Cacciari and Prader 1980

 Vascular Occlusion: Epidemiological, Pathophysiological and Therapeutic Aspects, Tesi and Dormandy 1981

38. Thymus, Thymic Hormones and T Lymphocytes, Aiuti and Wigzell 1980

*39. The Menopause: Clinical, Endocrinological and Pathophysiological Aspects, Fioretti, Mattini, Melis and Yen

40. The "Low T, Syndrome", Hesch 1981

- 41. Current Views on Insulin Receptors, Andreani, De Pirro, Lauro, Olefsky and Roth 1982
- 42. The Gonadotropins: Basic Science and Clinical Aspects in Females, Givens and Flamigni 1982
- 43. Medical and Surgical Problems of the Esophagus, Stripa, Belsey and Moraldi 1981

*44. Peripheral Arterial Diseases, Stipa and Cavallaro

45. Immunological Factors in Human Reproduction Shulman, Dondero and Nicotra 1982
 *46. Markers of Diagnosis and Monitoring of Human Cancer, Colnaghi, Buraggi and Ghione

48. Urokinase: Basic and Clinical Aspects, Mannucci and D'Angelo

*49. Pituitary Hormones and Related Peptides, M. Motta, M. Zanisi and F. Piva

^{*}At the time of going to press these titles were in preparation.

PREFACE

This volume is a record of papers presented at the second International Symposium on Urokinase held in Geneva, Switzerland, April 27-28, 1981. More than 200 participants attended this meeting at which there were sessions on the clinical use of urokinase in venous and arterial thromboembolism and on basic studies on urokinase.

Biochemists and pharmacologists have recently achieved new important results in this area and the first part of this volume includes a number of significant papers. On the other hand, clinicians are still working on urokinase in order to obtain the best results in thromboembolism and to avoid bleeding complications. No agreement has been reached either on the best treatment schedule or on the value of laboratory analysis for the steering of thrombolytic therapy toward success. The second part of this book illustrates the backgrounds of this controversy and is particularly dedicated to the clinicians fighting for therapeutic progress. It also explains why multicentre controlled trials are urgently needed.

The Editors are pleased to thank Professor F. Duckert for his invaluable help in the preparation of this Symposium and the Serono Institute who made it possible.

September 1981

P. M. MANNUCCI A. D'ANGELO roldings: Exerction After Experimentally Induced Renal Eather in the at by Folic Acid

by D. Ran, D. Maruton, K. D. Bock, E. Bombard and D. Locke . .

rokingse and Destran Submarc in the Enhancement of abinolytic Activity

by O. Marano.

Clinical Use of traditions in Venous and Arterial Thromboembolism
for Deep-wein Thrombosis

CONTENTE

Reembolytic Therapy in Deep Veila

Preface import at it what beside objected A representative viscos		
Basic Studies on Urokinase	kimas h ()	arij d
Urokinase: A Short Review of its Properties and of its Metabolism by Ph. Schneider, F. Bachmann and D. Sauser	us du usus X	1 A
Low Molecular Weight Urinary Urokinase by D. Gillessen, W. Lergier, R. O. Studer, J. Schaller, H. Nick and E. E. Rickli	firlia 21 vi shitta	6 2012 17
On the Structure of Urokinase—Characterization of Two Molecular Weight Forms	Mig Othu	a to out i
by A. Henschen, D. Sauser, F. Lottspeich, T. C. Wun and E. Reich Radioimmunoassays of High and Low Molecular Weight Urokinase	arti Mes	27
by L. Holmberg and B. Astedt The Expression of a Biologically Active Human Enzyme, Urokinase	degele edine en la a	33
in E. Coli by P. P. Hung	1 12251 131 1 15	43
and Urokinase by O. Matsuo, D. C. Rijken and D. Collen	•	55
Across the Intestinal Tract of Dogs and Human Subjects by K. C. Robbins, H. Sumi, K. Sasaki and N. Toki Urokinase Induction of Complement Alternate Pathway Activation	itioù.	63
in vitro by F. Laghi Pasini, A. Auteri, A. L. Pasqui and T. Di Perri	ir W surts	73
Urokinase Increases in vitro Vessel ADP-ase Activity and Inhibits ADP-induced Platelet Aggregation by F. Antonetti, F. Borrelli, L. Morelli, V. Pepe and L. Caprino	odan A a	79

Urokinase Excretion After Experimentally Induced Renal Failure in the Rat by Folic Acid	
by D. Paar, D. Maruhn, K. D. Bock, E. Bomhard and D. Lorke	85
Urokinase and Dextran Sulphate in the Enhancement of	
Fibrinolytic Activity	
by O. Matsuo	91
Clinical Use of Urokinase in Venous and Arterial Thromboembolism: In Deep-vein Thrombosis	
Clinical Guidelines and Expectations for Current and Future Thrombolytic	
Agents in the Therapy of Deep Vein Thrombosis	
by V. J. Marder	95
Arguments Favouring Laboratory Controls for the Guidance of Thrombolytic Therapy in Deep Vein Thrombosis	
by G. A. Marbet and F. Duckert	103
Laboratory and Clinical Evaluation of Five Urokinase Schemes in Acute and Subacute Deep Vein Thrombosis: A Nonrandomized Study in 34 Patients	i419a9
by H. Niessner, K. Lechner and E. Thaler	111
Urokinase Treatment in Acute and Subacute Deep Vein Thrombosis	3 4 4 7
by G. Trübestein, F. Etzel, Th. Brecht, M. Ludwig and G. Brecht	121
A Plebographically-controlled Pilot Study of the Effects of Different	
Urokinase Dosage Schedules in Deep Vein Thrombosis by A. D'Angelo, F. Porro, E. Rossi, A. Bonfalti, A. Lovaria	
大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大	133
and P. M. Munnucci Study Design and Progress of a Prospective, Multicenter Trial Comparing	100
Urokinase and Streptokinase in the Treatment of Deep Vein Thrombosis	
by W. Theiss and G. Trübestein Thrombolytic Treatment of Axillary-subclavian Venous Thrombosis	141
with Urokinase of the property of the particular training of medicanell as	140
by M. D'Addato and L. Pedrini	149
	18
Thrombolytic Therapy by H. C. Kwaan	153
Successful Therapy with Streptokinase and Urokinase in a Woman with	A NO
Budd-Chiari Syndrome	
by M. Barthels, W. Wellmann and K. Pries	163
	44
ginsport of High Molecular Weigin Hungan Ungage Unskingse v.	Ladj
In Pulmonary Embolism	Seros
Pulmonary Thromboembolic Disease: Management with Thrombolytic	
Agents	THE SHIP
by W. R. Bell Comparison of Heparin and Thrombolytic Agents in Clearing	. 169
Comparison of Heparin and Thrombolytic Agents in Clearing	
Thromboemboli from the Pulmonary Microcirculation by A. A. Sasahara, G. V. R. K. Sharma, V. A. Burleson, E. M. Barsamian,	HII/
by A. A. Sasanara, G. V. K. K. Sharma, V. A. Buneson, E. M. Barsannan,	10

Contents

13

The UK-PE Study Research Group: Multicentre Clinical Trial on Two		
Dose Regimens of Urokinase in Pulmonary Embolism		
by M. Brochier		191
Urokinase as Treatment for Massive Pulmonary Embolism		
by S. Milano, M. Zogno, L. Niccoli, V. Petroboni, C. Cuccia		
and G. Mombelloni		199
Lysyl-plasminogen, Defibrase and Human Plasmin Associated to		
Urokinase in the Treatment of Pulmonary Embolism		
by M. Brochier, P. Griguer and B. Charbonnier	11	203
by in Brother, 1. origin and b. orangoning		
In Arterial Thrombosis		
Thrombolytic Therapy for Thromboembolism of the Vertebrobasilar Ar	tery	
by G. G. Nenci, P. Gresele, M. Taramelli, G. Agnelli and E. Signorini		209
Urokinase Therapy in Newborn Infants with Aorto-Iliac Thrombosis		
by S. Rao, E. Chow-Tung, D. Flanigan, E. Pang and D. Vidyasagar		215
Urokinase in Opthalmology		
Hemorrhage into the Anterior Chamber: Treatment with Parabulbar-		
intracameral Injections of Urokinase		
by A. Vannini and M. Fagiano		223
Stimulation of Fibrinolysis in the Vitreous Body of the Eye		440
지하게 하는 것이 많아 많아 없었다면 하는 것이 없는데 나는데 없는데 나는데 없는데 나는데 없는데 없는데 없는데 없는데 없는데 없는데 없는데 없는데 없는데 없		227
		221
Urokinase in Vitreous Haemorrhage: A Prospective Clinical Trial		222
by J. V. Forrester and J. Williamson		233
Thrombolytic Therapy of Central Retinal Vein Occlusion: An Update		
by H. C. Kwaan, J. G. Dobbie and C. L. Fetkenhour		245
Ophthalmological Indications for Urokinase Therapy		
by A. P. Westerov, E. A. Egorov and A. A. Mozgov		249
Subconjunctival Urokinase for Retinal Vein Occlusion		
by B. Brancato and C. Michelone		253
Concluding Remarks		
by F. Duckert		259
		200

UROKINASE. A SHORT REVIEW OF ITS PROPERTIES AND OF ITS METABOLISM

Ph. Schneider, F. Bachmann and D. Sauser

Ph Softwarer et al.

Division of Haematology, University of Lausanne, School of Medicine, Lausanne and Hypolab S. A., Coinsins, Switzerland

The first International Symposium on Urokinase was held in Rome in 1975. At that time, many investigators had started clinical trials with urokinase and results of the UPET and of the USPET trials had just been published. However, in the great majority of countries, urokinase had not yet been registered. At the Rome meeting, basic studies on the purification and the properties of urokinase took up half of the scientific programme. Today, urokinase is registered in many countries and more than three-quarters of the present scientific programme deal with the clinical aspects of thrombolytic therapy with urokinase. Therefore, we thought it would be appropriate to begin this Symposium with a short review on the properties and metabolism of urokinase. In doing this, we will concentrate on newer findings of interest.

UROKINASE PRODUCTION SITES

Urokinase is not excreted into the urine as a waste product. It is produced by the kidneys and secreted into the urine to maintain patency of the urinary tract in case of haemorrhage. Barnett and Baron (1959) demonstrated that primary cultures of embryonic kidney cells were capable of producing urokinase. Bernik and Kwaan (1967) believe that this activity derives from endothelial cells of blood vessels which are present in embryonic kidney cells. Astedt (1975) found that freshly-isolated human glomeruli were fibrinolytically inactive. How-

Serono Symposium No. 48, "Urokinase: Basic & Clinical Aspects", edited by P. M. Mannucci and A. D'Angelo, 1982. Academic Press, London and New York.

ever, after organ culture of such glomeruli, marked release of plasminogen activator occurred. Paul et al. (1979) have demonstrated that urokinase is secreted by bleeding and vesiculation from a porcine kidney cell strain.

Over the past few years, different investigators discovered that many tumours such as carcinoma of the breast, the colon, the pancreas, the lung and of the ovary—produce an urokinase-like plasminogen activator (Astedt and Holmberg, 1976, Corasanti et al., 1980, Markus et al., 1980; Vetterlein et al., 1980; Wu and Yunis, 1979), whereas other tumours, such as melanoma, produce a plasminogen activator resembling tissue activator or vascular activator (Wilson et al., 1980; Rijken and Collen, 1981).

Shakespeare and Wolf (1979) claimed to have found significant quantities of urokinase in human whole blood. Using an anti-urokinase serum which gave at least five precipitin arcs against normal human serum, they found from 3 to 12 μ g of protein in human plasma, cross-reacting with their anti-urokinase anti-serum. At a specific activity of high M_r urokinase of approximately 100 000 IU/mg this would correspond to circulating urokinase level of 300 to 1200 IU/ml plasma! Asted and Holmberg (1979), on the other hand, using antibodies obtained by injection of a highly purified urokinase to rabbits, found only 4 to 8 ng of plasma proteins/ml precipitating with their anti-urokinase and interpreted this result as due to non-specific precipitation. Holemans *et al.* (1965) could not find urokinase in renal veins, even after histamine stimulation. Most investigators were not able to quench tissue activator or vascular blood activator activity with an anti-urokinase serum (Kucinski *et al.*, 1968; Kok and Astrup, 1969; Astedt, 1979; Binder *et al.*, 1979; Rijken *et al.*, 1980, 1981). These results demonstrate that the circulating fibrinolytic activators are clearly different from urokinase.

MOLECULAR FORMS OF UROKINASE

Urokinase appears to exist in several molecular forms. Very high molecular weight (M_r) forms of 100 to 200 kdaltons can be found in early tissue cultures and in freshly voided urine (Doleschel and Auerswald, 1967; Holmberg and Astedt, this volume p.33; Bobbit et al., 1980). There is some evidence that these forms represent a proactivator which can be converted into active urokinase upon incubation with small amounts of trypsin, plasmin, thrombin or Hageman factor fragments (Bernik and Oller, 1973; Maciag et al., 1977). A few investigators believe that these forms represent dimers of urokinase or complexes with other proteins, but Bobbitt et al. (1980) upon repeat gel filtration of pig kidney cells culture high Mr urokinase found substantial amounts in the 100 to 200 kdalton fractions and Markus (1980) observed that the 100 000 dalton forms cannot be disaggregated in 8m urea; these results represent a strong argument against complex or dimer formation. Several molecular forms of 46 to 60 kdaltons have been identified. Vetterlein et al. (1980) isolated a 60 000 and a 50 000 dalton urokinase from Detroit 562 (human pharyngeal carcinoma) and IMR-90 (human embryonic lung) cells. The former is clearly different from the classic high molecular weight urokinase, consisting of two chains and having a molecular weight of 54 000 (Lesuk et al., 1965). The classic low molecular

form of urokinase (White et al., 1966) consists probably of a family of degradation products with intact active sites and molecular weights around 32 000 (Lesuk et al., 1967; Huber and Binder, 1980).

Husain, Gurewich and Lipinski (1981) have recently isolated from freshly voided human urine a single-chain, high M_r urokinase, using affinity chromatography of fibrincelite. It has a molecular weight of approximately 56 kdaltons on SDS-polyacrylamid gel electrophoresis, remains intact after exposure to reducing agents and has a high affinity for fibrin. This single chain urokinase degrades into a double chain urokinase, unless protease inhibitors such as aprotinin or benzamidine are added to the urine (Fig. 1). It is not known, at the




Fig. 1. Conversion of single chain into double chain urokinase and into different low M_r forms.

present time, whether thrombin, plasmin and activated factor XII, which are known to convert an inactive proactivator in early tissue culture fluid into urokinase (Bernik and Oller, 1973; Maciag et al., 1977) are also capable of splitting the 56 kdalton single chain into the classic double chain urokinase. There are two ways to obtain active low molecular weight urokinase of about 33 kdaltons. The classic double chain urokinase of 54 kdaltons can be reduced to two chains: a light chain of approximately 21 and a heavy chain of 33 kdaltons (Fig. 1).

Proteolysis appears to affect primarily the light chain and results in products with molecular weights of 30 to 34 kdaltons, whose heavy chain remains mostly intact. Gillessen et al. report in this symposium (see p. 17) on sequence studies of such a low molecular weight from urokinase which still has a remnant of some 21 amino acids in its light chain. The N-terminal of the heavy chain consists of isoleucin.

STRUCTURE AND ACTIVITY OF UROKINASE

Urokinase (EC 3.4.99.26) is a serine protease. Landmann and Markwardt (1970) have demonstrated that the active site contains serine, and Ong et al. (1976) showed that alkylation of a histidine residue with chloromethylketones or its oxidations with performic acid resulted in loss of activity. Gillessen et al. have located the active site histidine in position 46 of the heavy chain. In general, serine proteases show considerable homology in their primary amino acid sequence and urokinase is no exception. Figure 2 demonstrates the homology of the first 6 N-terminal amino acids of urokinase, trypsin and of chymotrypsin.

Fig. 2. N-terminal homology of urokinase, trypsin and of chymotrypsin.

The primary action of urokinase on glu-plasminogen is probably the cleavage of an arginine-valine bond in the carboxy terminal region of the plasminogen molecule, resulting in a two chain glu-plasmin molecule (Robbins et al., 1967; Violand and Castellino, 1976; Christensen, 1977). As demonstrated in Fig. 3, glu-plasmin may then convert glu-plasminogen to met-, lys- or val-plasminogen (Wiman and Wallén, 1973; Rickli and Otavsky, 1973; Walther et al., 1975) by cleavage of one to three peptide bonds in the N-terminal portion of glu-plasminogen. Urokinase activates intermediate plasminogen to met-, lys- or val-plasmin by cleavage of the arginine-valine bond in position 560. Glu-plasmin is converted to met-, lys- or val-plasmin autocatalytically.

Robbins et al., (1979) have examined several urokinase preparations as to their steady state kinetic parameters of activation of native glu-plasminogen and of lys-plasminogen. All four preparations had apparent Michaelis constants of the same order of magnitude (1.7 – 7.4 μ m). Catalytic rate constants ranged from 28 to 78 per minute. Second order rate constants, a parameter which best indicates enzymatic efficiency, were 9 to 27 μ m⁻¹ min⁻¹. Although all these values are similar, each individual urokinase preparation had slightly different kinetic constants, suggesting structural differences in the enzyme species of each preparation.

Rijken (1980) compared the amidolytic activity of urokinase and of tissue activator on various synthetic substrates (Table I). The chromogenic tripeptide

a lacta chain of approximately 21 and a heavy claim of 33 telaflors (Fig. 1).




Fig. 3. Activation of glu-plasminogen to plasmin.

pyroglutamyl-glycylarginine-paranitroanilide S-2444 was most efficiently hydrolysed by urokinase. However, several other synthetic substrates are also hydrolysed by urokinase at varying efficacy. Urokinase split Chromozyn-Pl, a substrate developed for the determination of plasmin activity, surprisingly well.

UROKINASE INHIBITORS

Synthetic Inhibitors

Strong inhibitors of urokinase (Table II) are benzamidine, DFP and mercaptoethanol (Markwardt, 1978). The property of benzamidine to bind reversibly to urokinase has been successfully employed in purification procedures, using benzamidine-Sepharose as an affinity chromatography medium (Holmberg et al., 1976). The chloromethylketones TLCK and TPCK, which block the histidine group in the active site of urokinase, are rather weak inhibitors, as is iodoacetamide (Ong et al., 1976; Rijken, 1980). The ε-aminoacids EACA (epsilonaminocaproic acid), 6AHA (6-aminohexanoic acid) and AMCHA (tranexamic acid) are antifibrinolytic agents. However, they do not block the activation of plasminogen to plasmin by urokinase in concentrations up to 10 - 100 mm. On the contrary, they stimulate conversion of glu- and of lys-plasminogen to plasmin by urokinase, in concentrations of 0.01 - 10 mm for tranexamic acid, of 0.1 - 100 mm for aminohexanoic acid and of 1 - 1000 mm for lysine (Takada and Takada, 1980). This stimulation is thought to be due to conformational changes of the plasminogen molecule through interaction of its lysine binding sites with e-aminoacids.

Table I. Amidolytic activity of urokinase (UK) on synthetic substrates in comparison with

Substrate

 Δ A_{40s}/min × 10⁻³ UK TA Recommended Trypsin Plasmin Thrombin for Pyro-Glu-Gly-Arg-pNA Cbz-Val-Gly-Arg-pNA Tos-Gly-Pro-Lys-pNA Tos-Gly-Pro-Arg-pNA I-Glu-Gly-Arg-pNA Formula tissue activator (TA). Chromozym-Try Chromozym-Pl Chromozym-Th

From : Rijken (1980).

Table II. Synthetic inhibitors of urokinase.

3.4 TA unit is simplify regularized and A Plough units, shad the international unit (H), based on an luterna-	
Benzamidine	0.01
Diisopropylphosphofluoridate (DFP)	0.01
Mercaptoethanol	0.01
Phenylmethylsulphonylfluoride (PMSF)	0.1
Tosyllysinechloromethylketone (TLCK)	tion had 50 all on ed
Tosylphenylalaninechloromethylketone (TPCK)	50
Iodoacetamide	100 (1881) h

Natural Inhibitors

Several natural inhibitors of urokinase have been identified. The most important ones appear to be α_2 -antiplasmin, α_2 -macro-globulin, α_1 -antitrypsin and antithrombin III. Holmberg et al. (1980) demonstrated that, in human plasma, urokinase, but not DFP-inactivated urokinase, bound preferentially to α_2 -antiplasmin. Complex formation with α_2 -macroglobulin occurred equally well with native as with DFP-inactivated urokinase. These authors concluded, therefore, that an intact active site of urokinase is not necessary for complex formation with α_2 -macroglobulin. Valtera and Hamberg (1978) demonstrated that α_2 macroglobulin is capable of binding urokinase in a non-specific, probably electrostatic attachment that can be disrupted by isoelectric focusing, but not by gel filtration. Clemmensen and Christensen (1976) showed that α_1 -antitrypsin forms stochiometric complexes with urokinase. The inhibition of urokinase by antithrombin III appears to be accelerated in the presence of heparin (Clemmensen. 1978). This type of behaviour of antithrombin III has been observed with a number of other serine proteases, particularly with the active form of coagulation factors XI, IX, X and with thrombin. Many natural inhibitors, which are less well defined and may in part be different from those listed above, have been described in various body fluids and tissues. The subject has been recently reviewed by Hedner (1979) and Gallimore (1979). Hedner (1973, 1979) found an α₂-globulin plasma inhibitor of urokinase which did not cross-react with α_2 -macroglobulin, α_2 -antiplasmin or α_1 -antitrypsin. Campbell et al. (1980), Brakman and Astrup (1963) and Astedt et al. (1972) reported on an urokinase inhibitor, whose activity was markedly increased in plasma of pregnant women and suggested that it is produced by the placenta. Kawano et al. (1968), Holmberg and Astedt (1979) and Wijngaards (1979) were able to extract large quantities of an urokinase inhibitor from human placenta and Aznar et al. (1976) and Duthie et al. (1979) isolated it from aminotic fluid.

UROKINASE UNITS

Unfortunately, three different activity units are still in use. The first unit was described by Plough and Kjeldgaard (1957) and is still used by the manufacturers of Leo urokinase. In 1969, the Committee on Thrombolytic Agents

proposed the CTA unit, defined by the urokinase activity in three different assay systems: comprising a fibrinolytic, a caseinolytic and an esterolytic method (Johnson et al., 1969). One CTA unit is roughly equivalent to 0.74 Plough units. In 1969, the WHO established the international unit (IU), based on an International Reference Preparation, containing a mixture of high and low M_r urokinase. The IU is nearly identical with the CTA unit. Activity standardization of urokinase remains problematic because of the different behaviour of low and high M_r urokinase in different test systems (see below). However, these differences appear to be no larger than the inter-laboratory variation in relative potency estimation of urokinase, even when calibrating assays against the same standard (Gaffney et al., 1981). The international reference preparation of urokinase can be obtained from Dr Gaffney at the National Institute for Biological Standards and Control in Holly Hill, London. The authors strongly suggest that all manufacturers and researchers henceforth use the IU.

HIGH M_r VERSUS LOW M_r UROKINASE

For the last several years investigators and manufacturers of urokinase tried to solve the puzzle, which of the two commercially available forms of urokinase was more effective as a thrombolytic agent, the high M_r form, also called UK II or the low M_r form, also designated as UK I.

Samama and his group (1978), and other investigators as well, have observed that equal concentrations of UK II and UK I, as determined by amidolytic assays, yielded different lysis times when incorporated into human plasma clots. Using a plasma clot lysis time, UK I was less efficient and yielded in the average 1.5 times longer lysis times than an equivalent amount of UK II.

Suyama et al. (1977) compared the activity of high and low M_r urokinase in the Chandler's loop method. For the standardization of these two forms of urokinase they used an in vitro two-stage lysis time method. They observed that thrombus dissolution time was much shorter when using high M_r urokinase than with an equivalent amount of low M_r -urokinase. On the other hand, Marder et al. (1978), in patients with pulmonary embolism, observed the same plasma biochemical responses after administration of the activator, either purified from urine (40% high M_r and 60% low M_r urokinase) or from tissue culture (100% low M_r weight urokinase).

UROKINASE CLEARANCE

Plasma clearance rate studies have been performed after injection of human urokinase into animals or human beings (Tajima et al., 1974; Ueno et al., 1979; Woodard et al., 1970; Bachmann and Kulapongs, 1979 and 1980; Bachmann and Schneider, 1980; Matsuo et al., 1978; Matsuo and Mihara, 1977, Som et al., 1975; Barlow and Marder, 1980). The subject of urokinase metabolism has already been reviewed at the first Urokinase Symposium (Alkjaersig and Fletcher, 1977).

It is evident that the methodology used to determine urokinase in plasma